Insider Selling: Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Sells 8,879 Shares of Stock

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) CFO Mark Ragosa sold 8,879 shares of the stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total value of $205,104.90. Following the transaction, the chief financial officer now owns 23,382 shares of the company’s stock, valued at approximately $540,124.20. This trade represents a 27.52 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Mark Ragosa also recently made the following trade(s):

• On Monday, March 17th, Mark Ragosa sold 11,464 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $23.10, for a total value of $264,818.40.
• On Wednesday, March 12th, Mark Ragosa sold 36,372 shares of Kiniksa Pharmaceuticals stock. The shares were sold at an average price of $22.25, for a total value of $809,277.00.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $23.36 on Friday. Kiniksa Pharmaceuticals, Ltd. has a 52 week low of $16.56 and a 52 week high of $28.15. The stock has a market capitalization of $1.70 billion, a P/E ratio of -166.85 and a beta of 0.48. The stock has a 50-day simple moving average of $20.30 and a 200 day simple moving average of $22.07.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to the consensus estimate of $123.42 million. During the same quarter in the previous year, the business posted $0.35 EPS. The company’s revenue for the quarter was up 46.9% on a year-over-year basis. Research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Kiniksa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $37.17.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $50,000. Lazard Asset Management LLC acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $61,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Kiniksa Pharmaceuticals during the third quarter worth approximately $189,000. KLP Kapitalforvaltning AS acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $158,000. Finally, Bellevue Group AG acquired a new stake in Kiniksa Pharmaceuticals during the fourth quarter worth approximately $160,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.